RANNÍS, the Icelandic technology fund, has awarded Akthelia Pharma $330,000 for the initial development of its novel wound healing approach.
REYKJAVIK, Iceland -- June, 15, 2019 -- Akthelia Pharmaceuticals together with co-founder Prof. Gudmundur Gudmundsson has been awarded a RANNÍS grant from the Applied Research projects (Hagnýt rannsóknarverkefni) for the initial development of a novel wound healing technology. The total grant amounts to ISK 45 million over three years.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.
CONTACTS
Egill Masson CEO egill.masson@aktheliapharma.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland